http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Syndax to Participate in the BTIG Biotechnology Conference
-
Syndax to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 7, 2019
-
Syndax Pharmaceuticals (SNDX) Reports FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias
-
Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias
-
Syndax to Present at the JMP Securities Life Sciences Conference
-
Syndax to Present at the UBS Global Healthcare Conference
-
Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update
-
Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019
-
Syndax Pharmaceuticals (SNDX) Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA at AACR
-
Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meet
-
Syndax Pharmaceuticals (SNDX) Prices 4.366M Share Offering at $6/Sh
-
Syndax Announces $26.2 Million Offering of Common Stock and Warrants
-
Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update
-
Syndax to Present at the Cowen 39th Annual Health Care Conference
-
Syndax to Announce Fourth Quarter and Year-end 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019
-
Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019
-
Syndax Pharmaceuticals (SNDX) Announces 2019 Clinical and Corporate Outlook; Provides 2019 Financial Guidance
-
Syndax Highlights 2019 Clinical and Corporate Outlook
-
Syndax Pharmaceuticals (SNDX) Announces Presentation of Preclinical Data from Menin-MLL Program at ASH
-
Syndax Pharmaceuticals Announces Presentation of Preclinical Data from Menin-MLL Program at the 60th American Society of Hematology Annual Meeting
-
Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update
-
Syndax Pharmaceuticals Announces Presentations at the 60th American Society of Hematology Annual Meeting
-
Syndax to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 5, 2018
-
Syndax Pharmaceuticals (SNDX) Says Phase 3 Breast Cancer Trial E2112 Shows PFS not Statistically Significant
-
Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung
-
Syndax to Present at the 2018 Cantor Global Healthcare Conference
-
Syndax Pharmaceuticals (SNDX) Appoints Jennifer Jarrett and William Meury to Board Succeeding Luke Evnin Ph.D. and Henry Chen
-
Syndax Announces Changes to its Board of Directors
-
Syndax Pharmaceuticals (SNDX) Reports Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) in NSCLC
-
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer
-
Syndax to Present at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer
-
Syndax Announces Participation at Three Upcoming Investor Conferences
-
Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update
-
Syndax to Announce Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018
-
Pre-Open Movers 07/12: (ZGNX) (GLMD) (CA) Higher; (ZN) (ACRX) (AVGO) Lower (more...)
-
Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration
-
Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
-
Syndax (SNDX) Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA
-
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab)
-
Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update
-
Syndax to Announce First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 8, 2018
-
Syndax Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology Annual Meeting
-
Syndax to Present at the 2018 American Association for Cancer Research Annual Meeting
-
Syndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business Update
-
Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
-
Syndax to Announce Fourth Quarter and Year-end 2017 Financial Results and Host Conference Call and Webcast on March 5, 2018
-
Syndax Announces Presentations at the 2018 American Association for Cancer Research Annual Meeting
-
Syndax Pharmaceuticals (SNDX) Reports Immuno-Oncology Clinical Trial Collaboration with AstraZeneca
-
Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca
-
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

